| Novel 4-(morpholin-4-yl)-N′-(arylidene) benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations V Raparti, T Chitre, K Bothara, V Kumar, S Dangre, C Khachane, S Gore, ... European journal of medicinal chemistry 44 (10), 3954-3960, 2009 | 107 | 2009 |
| Discovery of CA-4948, an orally bioavailable IRAK4 inhibitor for treatment of hematologic malignancies VR Gummadi, A Boruah, BR Ainan, BR Vare, S Manda, HP Gondle, ... ACS Medicinal Chemistry Letters 11 (12), 2374-2381, 2020 | 40 | 2020 |
| Design, synthesis, and biological evaluation of phenyl thiazole-based AR-V7 degraders A Bhumireddy, NVMR Bandaru, BR Reddy, ST Gore, S Mukherjee, ... Bioorganic & Medicinal Chemistry Letters 55, 128448, 2022 | 13 | 2022 |
| Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313 SR Talapati, V Nataraj, M Pothuganti, S Gore, M Ramachandra, T Antony, ... Acta Crystallographica Section F: Structural Biology Communications 76 (8 …, 2020 | 7 | 2020 |
| Plasmodium chitinases: revisiting a target of transmission‐blockade against malaria VK Viswanath, ST Gore, A Valiyaparambil, S Mukherjee, ... Protein Science 30 (8), 1493-1501, 2021 | 4 | 2021 |
| Orally bioavailable SMARCA2 degraders with exceptional selectivity and potency C Abbineni, LK Satyam, B Kuila, A Ettam, KA Rawoof, S MR, SV Dukare, ... Cancer Research 81 (13_Supplement), 1144-1144, 2021 | 1 | 2021 |
| In silico designing of Targeted Protein Degraders S Mukherjee, ST Gore, MR Chandrasekhar Abbineni | 1 | 2020 |
| Targeting cancer with selective cbp/p300 bromodomain inhibitors M Jaleel, RS Senaiar, C Abbineni, GA Renukappa, S Mukherjee, ... Cancer Research 80 (16_Supplement), 1753-1753, 2020 | 1 | 2020 |
| Identification and characterization of paralogue selective CBP degraders for potential use in cancer therapy S Thiyagarajan, C Abbineni, K Chaitanya T, A Apte, IK Iqbal, N Kumar R, ... Cancer Research 84 (6_Supplement), 6065-6065, 2024 | | 2024 |
| Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies S Thiyagarajan, C Abbineni, K Chaitanya T, A Apte, IK Iqbal, N Kumar R, ... Cancer Research 84 (6_Supplement), 3303-3303, 2024 | | 2024 |
| 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders C Abbineni, S Samajdar, B Kuila, S Mukherjee, ST GORE US Patent App. 18/019,721, 2024 | | 2024 |
| Abstract A046: Identification of paralog selective degraders of SMARCA2 and SMARCA4 for treatment of various cancers C Abbineni, K Aithal, L Khare, SD V, B Kuila, M Goyal, KA Rawoof, ... Molecular Cancer Therapeutics 22 (12_Supplement), A046-A046, 2023 | | 2023 |
| Abstract B172: Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor L Khare, R Poddutoori, S Mukherjee, S DS, D TS, S Marappan, S Nayak, ... Molecular Cancer Therapeutics 22 (12_Supplement), B172-B172, 2023 | | 2023 |
| Heterocyclic compounds as cbp/ep300 bromodomain inhibitors C Abbineni, S Samajdar, RS Senaiar, GA RENUKAPPA, S Mukherjee, ... US Patent App. 18/044,329, 2023 | | 2023 |
| Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers C Abbineni, S Thiyagarajan, A AB, AA Dhudashiya, S Marappan, ... Cancer Research 82 (12_Supplement), 4114-4114, 2022 | | 2022 |
| Discovery of orally bioavailable SMARCA2/4 dual degraders for treatment of acute myeloid leukemia C Abbineni, L Khare, B Kuila, AR Khaji, DB Mahadeo, SV Dukare, ... Cancer Research 82 (12_Supplement), 3729-3729, 2022 | | 2022 |
| Structural and binding studies of cyclin‐dependent kinase 2 with NU6140 inhibitor SR Talapati, M Goyal, V Nataraj, M Pothuganti, S Gore, M Ramachandra, ... Chemical Biology & Drug Design 98 (5), 857-868, 2021 | | 2021 |
| Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers C Abbineni, S Thiyagarajan, RS Senaiar, S Mukherjee, M Jaleel, ... Cancer Research 81 (13_Supplement), 1143-1143, 2021 | | 2021 |
| First in class orally bioavailable BETBRD degraders C Abbineni, M Jaleel, S Mukherjee, S Marappan, NK Tiwari, DS Samiulla, ... Cancer Research 80 (16_Supplement), 1754-1754, 2020 | | 2020 |
| Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12 R Poddutoori, S Rajagopalan, S Mukherjee, S Marappan, S DS, ... Cancer Research 79 (13_Supplement), 4418-4418, 2019 | | 2019 |
